Canada Pension Plan Investment Board Makes New Investment in Sana Biotechnology, Inc. $SANA

Canada Pension Plan Investment Board bought a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 10,218,400 shares of the company’s stock, valued at approximately $35,662,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Legal & General Group Plc purchased a new position in shares of Sana Biotechnology in the 2nd quarter valued at about $475,000. The Manufacturers Life Insurance Company purchased a new stake in Sana Biotechnology during the second quarter worth about $286,000. Ieq Capital LLC purchased a new stake in Sana Biotechnology during the second quarter worth about $449,000. Callan Family Office LLC acquired a new position in Sana Biotechnology during the second quarter worth about $43,000. Finally, LaSalle St. Investment Advisors LLC acquired a new position in Sana Biotechnology during the second quarter worth about $77,000. 88.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on SANA. Weiss Ratings upgraded shares of Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 23rd. Bank of America lowered their price target on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, August 14th. TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research note on Monday. Rodman & Renshaw initiated coverage on Sana Biotechnology in a report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research report on Monday, July 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.33.

Sana Biotechnology Trading Down 1.7%

Shares of SANA opened at $4.09 on Friday. The stock has a market cap of $1.22 billion, a P/E ratio of -5.38 and a beta of 2.16. The company has a 50-day moving average of $3.56 and a two-hundred day moving average of $3.41. Sana Biotechnology, Inc. has a 12-month low of $2.61 and a 12-month high of $6.55.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. As a group, analysts forecast that Sana Biotechnology, Inc. will post -0.72 EPS for the current fiscal year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.